An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression

Currently, no head-to-head data are available comparing semaglutide 2.0 mg with dulaglutide 3.0 mg or 4.5 mg. We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes. Multilevel network meta-regression was c...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2022-04, Vol.107 (5), p.1461-1469
Main Authors: Lingvay, Ildiko, Bauer, Robert, Baker-Knight, James, Lawson, Jack, Pratley, Richard
Format: Article
Language:English
Subjects:
Body Weight
Clinical Trials as Topic
Comparative analysis
Diabetes Mellitus, Type 2 - drug therapy
Glucagon-Like Peptides - adverse effects
Glucagon-Like Peptides - analogs & derivatives
Glycated Hemoglobin A - analysis
Glycosylated hemoglobin
Humans
Hypoglycemic Agents - adverse effects
Immunoglobulin Fc Fragments - adverse effects
Medical research
Medicine, Experimental
Meta-Analyses
Pharmaceutical industry
Recombinant Fusion Proteins - adverse effects
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, no head-to-head data are available comparing semaglutide 2.0 mg with dulaglutide 3.0 mg or 4.5 mg. We conducted an indirect treatment comparison (ITC) of their effects on glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes. Multilevel network meta-regression was conducted, based on a connected evidence network of published results from the A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes 11 trial and individual patient data from the A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN) and SUSTAIN 7 trials. Semaglutide 2.0 mg significantly reduced HbA1c vs dulaglutide 3.0 mg and 4.5 mg, with estimated treatment differences (ETDs) of -0.44% points (95% credible interval [CrI], -0.68 to -0.19) and -0.28% points (95% CrI, -0.52 to -0.03), respectively. Semaglutide 2.0 mg also significantly reduced body weight vs dulaglutide 3.0 mg and 4.5 mg with ETDs of -3.29 kg (95% CrI, -4.62 to -1.96) and -2.57 kg (95% CrI, -3.90 to -1.24), respectively. Odds of achieving HbA1c 
ISSN:0021-972X
1945-7197
DOI:10.1210/clinem/dgab905